AbbVie Says Acute Myeloid Leukemia Trial Meets Endpoints

AbbVie Inc. said its trial of venclexta in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints.
The trial met the endpoints of statistically significant improvement of overall survival and composite complete remission rate for patients with previously-untreated acute myeloid leukemia who are ineligible for intensive chemotherapy.
At the recommendation of an independent data monitoring committee due to positive efficacy results at the first interim analysis for overall survival, the trial results will be reported early and the data from the trial will be submitted to the U.S. FDA and global health authorities.
Results will be presented at a future medical meeting or published in a peer-reviewed journal, the company said.
Venclexta is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

https://www.marketscreener.com/ABBVIE-INC-12136589/news/AbbVie-Says-Acute-Myeloid-Leukemia-Trial-Meets-Endpoints-30213254/